INTRODUCTION
Two drugs are bioequivalent if they contain the same active substance in the same or similar pharmaceutical form at the same molar dose and if the rate and extent of absorption from the administered dosage form are the same within specific limits.
Data sets usually contain some extraordinary measures.
It is one of the most commonly encountered problems in bioequivalence studies. These extraordinary measures are called outliers and may affect bioequivalence results. It might be mistakenly concluded that formulations are not bioequivalent even if in fact they are, or bioequivalent if in reality they are not. Hence outliers should be analyzed carefully to avoid these mistaken conclusions.
Since including or excluding outliers in bioavailability/ bioequivalence studies causes different inferences, many researchers have worked on this topic in the past (1) (2) (3) (4) . Chow and Tse (1990) have proposed two procedures for detection of a possible outlier in bioequivalence studies based on Cook's likelihood distance and the estimates distance (3). Liu and Weng (1991) examined procedures based on Hotelling T 2 statistics and residuals for the same purpose (5) . Wang and Chow (2003) introduced a general test procedure based on a mean-shift model (6) .
In this study, we aimed to introduce methods that may be used to examine outliers and apply them to a real data set of a real bioequivalence analysis.
METHODS

Important Concepts and Outliers in Bioequivalence Studies
Bioequivalence is mainly considered when there is the same active substance within different drugs. Studies investigating the bioavailability of two pharmaceutically bioequivalent drugs whether they are the same or not, after administering the same molar dose, are called bioequivalence studies (7) .
"The reference drug" is the compound that was developed first and obtained approval to be marketed to treat a condition after it showed satisfactory efficacy and safety. After the patent/data protection duration of the innovating firm on the reference drug has expired, the products that are introduced to the market by other pharmaceutical companies, are called "equivalent drugs", meaning they are pharmaceutical equivalents or alternatives to the original medicine. In bioequivalence studies, these drugs are called the "test" products.
The most widely used pharmacokinetic parameters in bioequivalence studies are as follows: Area under the concentration curve (AUC), maximum plasma concentration (C max ), and time to reach maximum plasma concentration (t max ).
For two formulations to be considered as bioequivalent, the FDA regulations require that the limits of a 90% confidence interval for the ratio of the geometric means of the two kinetic responses (AUC and C max ) should be within the interval of [80%-125%] (8).
The average, population, and individual bioequivalence methods are used in bioequivalence studies (9) (10) (11) .
Generally the utilized design is a 2x2 crossover, which takes into account period and formulation effects. The likelihood function for a 2x2 crossover design is
where θ parameter vector is (θ 1 , θ 2 , θ 3 ) T . The maximum likelihood estimator (MLE), which makes maximum the likelihood function in Equation (1), is
where, f is the number of formulations, n is the number of subjects, and Y ij expresses the measurement value for i th subject, j th formulation (3). Outliers can be described as data that are incompatible with other data in a data set. Incompatibility between data is an undesirable condition because of it has an important effect on statistical studies (12) (13) (14) .
Outliers in bioavailability/bioequivalence studies may occur because of fluctuation in laboratory tests, for example an extraordinary subject having too high or too low bioavailability, or humanistic measuring faults.
The methods, that are used for detecting outliers in bioequivalence studies are explained below.
Likelihood Distance Test
The likelihood distance test (LD) is one of the tests used for determining outliers or influential observations in a bioequivalence study and was developed by Cook and Weisberg (1982) based on likelihood distances.
The LD statistic for the i th subject is twice of the difference between the log likelihood evaluated by using the estimates from all of the subjects and from the estimates obtained after deleting the i th subject. This is expressed as:
, where, î   is the maximum likelihood estimator of θ obtained by deleting the i th subject from the data.
Asymptotically, ) θ ( LD iˆ is distributed as a chisquare statistic with three degrees of freedom. If
, the i th subject is an outlier (3).
Estimates Distance Test
The second method for examining the effect of i th subject in the study is based on the difference in the parameter estimates arising from the deletion of the i th subject. Estimates distance test (ED) is similar to the LD because of accounting the distances of parameter estimates in the case of the presnce or absence of the i th subject. The ED statistic is ) 
Hotelling T 2 Test
Liu ve Weng (1991) suggested a procedure based on the order statistics of the two sample Hotelling T 2 (HT) statistics to identify possible outlying subjects. Let In this case, HT statistic for the i th subject is given by
The value, which is obtained from Equation (5), is compared with the critical value to decide whether or not the i th subject is an outlier (5).
Liu and Weng's Residuals Test
Liu and Weng (1991) suggested a test for determining outliers benefiting from the means of the formulation. Let j .
Y be the j th formulation mean. Studentized residuals are obtained as r ij (i=1, 2, …, n; j=1, 2, .., f). Maximum values of standardized residuals are compared with a critical value to decide whether or not the i th subject is an outlier (5). 
Mean Shift Test
In Equations (6) and (7); e t is the vector of residuals for the t th subject, t e represents the mean of e t , 1 is a vector whose members are 1. Then, they showed that the test statistic n 2 n 1 t nT nT D   (8) can be used to test whether the t th subject is an outlier, or not (6) .
To test the practicality of outlier examination methods by using 2x2 crossover method that is applied to two different pharmacokinetic profiles' bioequivalence by Novagenix Bioanalytical Drug R.D. Center we used a real data set taken from 23 volunteers at 21 different time points.
The participants in this study provided voluntary informed consent. This study was approved by a local institutional review board and was conducted in accordance with the Declaration of Helsinki.
Microsoft Excel 2007 was used for statistical analysis.
RESULTS
After administering the test and reference drugs, involving the same active substance, to 23 subjects in the study, measures were taken from the blood at 21 time points. The AUC parameters, which were calculated for test and reference drugs for any subject, are seen in Figure 1 .
When Figure 1 is analyzed, it may be seen that a minimum value was measured for the 6 th subject and this subject is different from the other subjects. It may be speculated that the 6 th subject is an outlier, because outliers in the test drug levels have a converter effect on the results of the study. Whether or not the 6 th subject was an outlier was evaluated by using the outlier examination methods as previously described.
Likelihood Distance Test
Estimators of the maximum likelihood function in Equation (1) are obtained as 1 = 9.192; 2 = 0.1569, and 3 = 0.2056 by using Equation (2) . To determine, whether the 6 th subject is an outlier or not, the 6 th subject was deleted from the data and estimators were calculated as 1-6 = 9.239; 2-6 = 0.0241, and 3-6 = 0.1157. For 1 , 2 , 3 , the likelihood function value in Equation (1) 
Estimates Distance Test
For this test, the ED statistic was calculated using Equation (3). The 6 th subject's ED statistic was detected as 32.8991. As 
Hotelling T 2 Test
For testing whether or not the 6 th subject was an outlier, the 2 6 D statistic for the 6 th subject was calculated as 0.93 by Equation (4). This value was used in Equation (5) and the 2 6 T statistic for the 6 th subject was calculated as 751.15. This value was greater than the critical value of 21.88 for T 2 order statistics at α=0.05 significance level with a sample size 23. Therefore, the 6 th subject was an outlier.
Liu and Weng's Residuals Test
In this test, outliers were determined by using residuals (e i ). Standardized residuals (r i ) were obtained by dividing calculated residuals by the standard deviation (0.4183) and these values were compared with the critical value of 2.83 at α=0.05, n=23, and p=3.
The maximum residual value (5.223) was obtained at the sixth subject's test drug level. The sixth subject was an outlier because this value was greater than the critical value of 2.83.
Mean Shift Test
In this study, T 1n , T 2n , and D t statistics were calculated using Equation (6), Equation (7), and Equation (8) 
Bioequivalence Examination
From all of the tests for the analysis of outliers, it was concluded that the sixth subject was an outlier. The effect of this subject on the result of the bioequivalence study was examined by the average bioequivalence method.
Ninety percent confidence intervals of test/reference proportions of AUC, which are obtained using the data with and without the sixth subject by plasma concentrations in the subjects' blood, are given at Table  1 .
When Table 1 is examined, it is seen that decision parameter maximum and minimum limits of AUC's proportions are within the 80%-125% limits. The inclusion of the sixth subject in the study did not change the bioequivalence result but decreased the similarities of test and reference drugs by changing the results at the test drug level, as seen by the means of test/reference drug ratio (p=0.4>0.05). When the sixth subject is deleted, the mean of the test/reference drug ratio became closer to 1. Metzler and Huang (1983) have demonstrated that the existence of outliers has no significant effect on bioequivalence studies. Chow and Tse (1990) and Bolton (1991) In this study, likelihood distance, estimates distance, Hotelling T 2 , mean-shift test, and Liu and Weng's residuals method have been applied on a real data set and it is concluded that the sixth subject is an outlier.
DISCUSSION
For examining the effect of the sixth subject on bioequivalence results, the average bioequivalence method proposed 2x2 crossover designs are used in both the presence and absence of the sixth subject in the data. It was concluded that the sixth subject did not change the bioequivalence results, but the similarities of the drugs were less in the study when the sixth subject was involved.
From the results of the average bioequivalence method, it should not be thought that the sixth subject had no effect on the results, because the sixth subject had a masking effect on the mean of the test drug and this effect should be taken into the consideration in the comparison. 
